Induction of antigen specific immunologic tolerance

Details Induction of antigen specific immunologic tolerance Induction of antigen specific immunologic tolerance

2002-05-06

2009-02-03

Belyavskyi, Michail A (Department: 1644)

Drug, bio-affecting and body treating compositions

Nonspecific immunoeffector, per se ; or nonspecific...

C424S094100

Reexamination Certificate

active

07485314

ABSTRACT:
Antigen specific immune tolerance is induced in a mammalian host by administration of a toleragen in combination with a regimen of immunosuppression. The methods optionally include a preceding conditioning period, where immunosuppressive agents are administered in the absence of the toleragen. After the tolerizing regimen, the host is withdrawn from the suppressive agents, but is able to maintain specific immune tolerance to the immunogenic epitopes present on the toleragen. Optimally, the toleragen will have high uptake properties that allow uptake in vivo at low concentrations in a wide variety of tolerizing cell types.

REFERENCES:
patent: 4117118 (1978-09-01), Harri et al.
patent: 5135915 (1992-08-01), Czarniecki et al.
patent: 5597563 (1997-01-01), Beschorner
patent: 5747034 (1998-05-01), de Boer et al.
patent: 5837812 (1998-11-01), Harrison et al.
patent: 6149909 (2000-11-01), Scott et al.
patent: 2005/0191309 (2005-09-01), Kakkis et al.
patent: WO 96/23882 (1996-08-01), None
patent: WO-98/37917 (1998-09-01), None
Tisch et.al. Antigen-specific immunotherapy: Is it a real possibility to combat T-cell-mediated autoimmunity?, PNAS, 1994; 91: 437-438.
Marketletter, Markletter Publications Ltd. 1999. Autoimmune shares collapse on colorectal data in rheumatoid arthritis.
Goodnow C. Pathways for self tolerance and the treatment of autoimmune diseases. The Lancet. 2001; 357: 2115-2121.
Shimizu et.al. Stimulation of CD25+CD4+ regulatory T cells through GITR breaks immunological self-tolerance. Nature Immunology. Feb. 2002; 3: 135-142.
Indar et.al. Current concepts in immunotherapy for the treatment of colorectal cancer. Clinical review. 2.
Auchincloss H. chapter 11 in Transplantation Immunology, Bach and Auchincloss Eds. Wiley-Liss, New York, 1995, pp. 211-218,).
Kakkis et. al. Overexpression of the human lysosomal enzyme alpha-L-iduronidase in chinese hamster ovary cells. Protein Expression and Purification. 1994; 5: 225-232.
Kakkis et al., N Engl J Med. Jan. 18, 2001;344(3):182-8.
Holhfeld et al., Proc Natl Acad Sci U S A. Oct. 5, 2004;101 Suppl 2:14599-606.
Rosenberg et al., Blood. Mar. 15, 1999;93(6):2081-8.
Doug Brooks, Mol Genet Metab. Oct. 1999;68(2):268-75.
McHeyzer-Williams et al., Curr Opin Immunol. Apr. 1999;11(2):172-9.
Bemer et al., Eur J Immunol. Dec. 1995;25(12):3394-401.
Corsini et al., Neurol Sci. Apr. 2000;21(2):87-91.
Adams et al., “Conventional immunosuppression and co-stimulation blockade”, The Royal Society, (2001), doi 10.1098/rstb.2001.0854, pp. 703-705.
Aledort et al., “Inhibitors in Hemophilia Patients: Current Status and Management”, American Journal of Hematology, (1994), 47: 208-217pp. 208-217.
Amalfitano et al., “Recombinanat human acid α-glucosidase enzyme therapy for infantile glycogen storage disease type II: Results of a phase I/II clinical trial”, Genetics in Medicine, (2001), vol. 3, No. 2, pp. 132-138.
Chaffee et al., IgG Antibody Response to Polyethylene Glycol-modified Adenosine Deaminas in Patients with Adenosine Deaminase Deficiency, J. Clin. Invest., (1992), vol. 89, pp. 1643-1651.
Chao et al., “Induction of tolerance to human Factor VIII in mice”, Blood, (2001), vol. 97, No. 10, pp. 3311-3312.
Diasio et al., “Immunomodulators: Immunosuppressive Agents and Immunostimulants”, Goodman and Goodman, Chapter 52, pp. 1291-1308.
Gossain et al., “Systemic Allergy to Human (Recombinant DNA) Insulin”, Annals of Allergy, (1985), vol. 55, pp. 116-118.
Kakkis et al., “Enzyme-Replacement Therapy in Mucopolysaccharidosis I”, The New England Journal of Medicine, (2001), vol. 344, No. 3, pp. 182-188.
Kakkis et al., Long-Term and High-Dose Trials of Enzyme Replacement Therapy in the Canine Model of Mucopolysaccharidosis I1, Biochemical and Molecular Medicine, (1996), vol. 58, Article No. 0044, pp. 156-167.
Kakkis et al., “Overexpression of the Human Lysosomal Enzyme α-L-Iduronidase in Chinese Hamster Ovary Cells”, Protein Expression and Purification, (1994), vol. 5, pp. 225-232.
Kirk et al., “Immunosuppression without immunosuppression? How to be a tolerant individual in a dangerous world”, Basic Science, (1999), vol. 1, pp. 65-75.
Krensky et al., “Immunologic tolerance”, Pediatr Nephrol, (2001), vol. 16, pp. 675-679.
Lechler et al., “T-cell anergy and peripheral T-cell tolerance”, The Royal Society, (2001), vol. 356, pp. 625-637.
Richards et al., “Antibody Response in Patients With Gaucher Disease After Repeated Infusion With Macrophage-Targeted Glucocerebrosidase”, Blood, (1993), vol. 82, No. 5, pp. 1402-1409.
Rossi et al., “Long-term induction of immune tolerance after blockade of CD40-CD40L interaction in a mouse model of hemophilia A”, Blood, (2001), vol. 97, No. 9, pp. 2750-2757.
Sebille et al., “Mechanisms of tolerance induction: blockade of co-stimulation”, The Royal Society, (2001), vol. 356, pp. 649-657.
Shull et al., “High Frequency of Acute Promyelocytic Leukemia Among Latinos With Acute Myeloid Leukemia”, Blood, (1996), vol. 88, No. 1, pp. 377-379.
Shull et al., “Enzyme Replacement in a Canine Model of Hurler Syndrome”, National Academy of Sciences, (1994), vol. 91, Issue 26, pp. 12937-12941.
Stockinger et al., “T Lymphocyte Tolerance: From Thymic Deletion to Peripheral Control Mechanisms”, Advances in Immunology, (1999), vol. 71, pp. 229-265.
Wilson et al., “Immunomodulation to enhance gene therapy”, Nature Medicine, (1995), vol. 1, No. 9, pp. 887-889.
Pozzilli et al.,Diabetologia, 43:1000-1004 (2000).
Schroeder et al.,J. Surg. Res., 111:109-119 (2003).
Tough et al., Fundamental Immunology, 5th Ed. (2003), ed. William E. Paul, Lippincott Williams and Wilkins, p. 865.
International Preliminary Examination Report for International Application No. PCT/US03/13843, dated Mar. 13, 2006.
International Search Report for International Application No. PCT/US03/13843, dated Dec. 11, 2003.
Brady et al., “Management of neutralizing antibody to ceredase in a patient with type 3 gaucher disease,”Pediatrics, 100: E11 (1997).
Kakavanos et al., “Immune tolerance after long-term enzyme-replacement therapy among patients who have mucopolysaccharidosis I,”Lancet, 361:1608-1613 (2003).
Ponce et al., “Enzyme therapy in gaucher disease type 1: effect of neutralizing antibodies to acid β-glucosidase,”Blood, 90:43-48 (1997).

Affiliated with

Also associated with

Rating

Induction of antigen specific immunologic tolerance does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Induction of antigen specific immunologic tolerance, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Induction of antigen specific immunologic tolerance will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4087737